

IFW



Attorney Docket No.: VPI/02-115 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Jingrong Cao, et al.
CONFIRMATION NO.: 8080
SERIAL NUMBER: 10/696,862 EXAMINER: Not Yet Assigned
FILING DATE: October 30, 2003 ART UNIT: 1614
FOR: COMPOSITIONS USEFUL AS INHIBITORS OF ROCK AND OTHER
PROTEIN KINASES

June 9, 2004
Cambridge, Massachusetts

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants hereby make of record the documents listed on the modified Form PTO-1449 (submitted in duplicate) in the above-identified application.

This Information Disclosure Statement is being been filed:

- ☐ within three months of the filing date of the National Application;
- ☐ within three months of the filing date of the entry of the National Stage, as set forth in 37 C.F.R. §1.491, in an International Application; or
- ☒ before the mailing date of a first Office Action on the merits in the above-identified case.

Accordingly, no fee or certification is required (37 C.F.R. §1.97).


A copy of the references are enclosed unless otherwise indicated on the attached Form PTO-1449 (modified). It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

APPLICANTS: Cao, et al.
U.S.S.N.: 10/696,862

Applicants also request that 1) a copy of the enclosed form PTO-1449 duly initialed by the Examiner be forwarded to the undersigned with the next communication; and 2) the enclosed be printed on any patent that may issue for this application.

The Commissioner is hereby authorized to charge any additional fees that may be due, or credit any overpayment to Deposit Account No. 50-0725, Reference No. VPI/02-115 US.

Respectfully submitted,



Nandakumar Govindaswamy, Ltd. Recognition
Attorney for Applicants
c/o Vertex Pharmaceuticals Incorporated
130 Waverly Street
Cambridge, Massachusetts 02139
Tel: (617) 444-6619
Fax: (617) 444-6483




**BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE
UNITED STATES PATENT AND TRADEMARK OFFICE**

LIMITED RECOGNITION UNDER 37 CFR § 10.9(b)


Nandakumar Govindaswamy is hereby given limited recognition under 37 CFR §10.9(b) as an employee of Vertex Pharmaceuticals, Inc. to prepare and prosecute patent applications wherein the patent application is assigned to Vertex Pharmaceuticals, Inc., and the attorney or agent of record in the applications is a registered practitioner who is an employee of Vertex Pharmaceuticals, Inc. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) Nandakumar Govindaswamy ceases to lawfully reside in the United States, (ii) Nandakumar Govindaswamy's employment with Vertex Pharmaceuticals, Inc. ceases or is terminated, or (iii) Nandakumar Govindaswamy's current Employment Authorization card expires.

This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the U.S. Patent and Trademark Office.

Expires: December 1, 2004



Harry Moatz,
Director of Enrollment and Discipline



Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/696,862
	Filing Date	October 30, 2003
	First Named Inventor	Jingrong Cao
	Group Art Unit	1614
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	VPI/02-115 US

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number		Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
	B1	WO	02/14311 A2	Amgen Inc.	21 February 2002		
	B2	WO	00/26202	Pharmacia & Upjohn S.P.A.	11 May 2000		
	B3	EP	1 205 478 A1	Takeda Chemical Industries, Ltd.	15 May 2002		
	B4	WO	00/26203	Pharmacia & Upjohn S.P.A.	11 May 2000		
	B5	WO	01/17995 A1	Merck & Co., Inc.	15 March 2001		
	B6	EP	1 256 578 A1	Pfizer Products Inc.	13 November 2002		
	B7	WO	02/096905 A1	Vertex Pharmaceuticals Incorporated	5 December 2002		

OTHER NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. § 120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.



Our Docket No.: VPI/02-115 US

Certificate Of Mailing Under 37 CFR §1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On June 8, 2004
Date

1. Information Disclosure Statement (2 pages, in duplicate);
2. PTO-1449 Form (1 page, in duplicate);
3. Copy of International Search Report;
4. Cited References (B1-B7); and
5. This Return Postcard Receipt.

Karen DiRocco

Typed or printed name of person signing Certificate

Karen DiR

Signature